Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study

Documenti analoghi

• Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
  di: Dahlberg, Suzanne E., et al.
  Pubblicazione: (2010)
• Prognostic Models to Predict Survival in Non-Small Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab
  di: Hoang, Tien, et al.
  Pubblicazione: (2012)
• Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)
  di: Wanebo, H. J., et al.
  Pubblicazione: (2014)
• Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)
  di: Hanna, Nasser H., et al.
  Pubblicazione: (2015)
• Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
  di: Flaherty, Keith T., et al.
  Pubblicazione: (2013)